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Spasticity could represent a complication of several central nervous system (CNS) 
disorders. Multiple sclerosis and painful paroxysmal syndromes (e.g. trigeminal 
neuralgia) are pathologies in which anti-spastic drugs are used to a greater extent . 
Baclofen, tizanidine (TIZ), benzodiazepines, dantrolene, and, more recently, gabapen-
tin are the pharmacological agents more widely used. Baclofen, TIZ, benzodiazepines, 
gabapentin, clonidine but not dantrolene are active on CNS. The  alpha2 adrenocep-
tor agonist TIZ is one of the most eff ective and largely used  anti-spastic drugs. Oral 
treatment is the only route of anti-spastics administration, although it may cause 
problems of bioavailability and/or compliance in spastic patients with impaired 
deglutition. This study was designed to assess the possibility of develop a new  route 
of administration of TIZ and to identify its targets in the spinal cord. 
New Zealand rabbits were treated with oral (OR , n=6), intramuscular (IM, n=6) 
or  intranasal (IN, n=6) TIZ (3.2 mg/kg/day). Plasma concentration was measured by 
HPLC on samples collected at 0, 30, 60, 90, 120 and 480 min after treatment. Curves 
of average concentrations of TIZ vs. time were constructed. In plasma, TIZ reached a 
peak between 45-65 min after administration. Cmax was in the range of 268.33–1213.64 
ng/ml for IM treatment, of 73.95–135.92 ng/ml for IN treatment and of 16.86–857.25 
ng/ml for OR treatment. After pharmacokinetic studies, diff erent spinal cord tracts 
were removed and used for radioligand binding assay and autoradiography. Using 
[3H]-RX821002 ([3H]-RX) (0.1-14nM), the Kd and Bmax for every spinal cord segment 
were calculated. The non-specifi c binding was obtained with 100μM of (-)-epineph-
rine. [3H]-RX sites were accumulated in the superfi cial laminae of dorsal horn. Dense 
[3H]-RX binding in control was seen over the superfi cial dorsal horn (laminae I-II) 
and centrally located lamina X. The ventral horn showed moderate levels of binding. 
[3H]-RX was displaced after TIZ treatment using diff erent administration routes. The 
heaviest accumulation of silver grains (lowest displacement of TIZ) occurred after OR 
administration of the compound, the lowest after IM administration. These results 
suggest that both IM and IN administration of TIZ may represent routes of adminis-
tration of the drug alternative to the OR one. 
Considering predictable adverse eff ects of IM treatment, the IN administration 
could represent the elective route to administrate this kind of drugs.
